Uniting in Action for a Healthier Middle East – Yahoo Finance
Pharmacists and Healthcare Professionals from >11 countries to converge at the ‘1st P&G Health Middle-East Whole Body Health Symposium’
Accredited by ‘Saudi Commission of Health Specialists’, the symposium will see leading global and regional experts deliberate on ‘Total Body Health’ and the role of Pharmacists in education, awareness, and consumer care
DUBAI, UAE, Sept. 16, 2022 /PRNewswire/ — In the run-up to World Pharmacists Day 2022, P&G Health, the health care division of Procter & Gamble is bringing together Pharmacists and Healthcare Professionals from across 11 countries in the Middle East to highlight the importance of ‘Total Body Health’ for the collective well-being of consumers and communities. The symposium will see the presence of leading global and regional healthcare experts deliberating on ‘Total Body Health’ topics ranging from Oral Health and General Health to Maternal Health and Non-Communicable Diseases with focus on the key role of Pharmacists in timely diagnoses, education, and management.
“Pharmacies today are an integral part of the healthcare system. With pharmacists being among the first line of contact for patients, they are well positioned in the community to have a significant impact on public health. Our ‘1st P&G Health Middle-East Whole Body Health Symposium’ is part of our continued efforts to advance important discussions within countries and regionally on the important role Pharmacists can play in a consumer’s healthcare journey right from raising symptom awareness to effective intervention and promoting health-seeking behaviors,” stated Dr Ashley Barlow, Senior Director, Medical & Technical Affairs, P&G Health – Asia Pacific, India, Middle East, and Africa.
Did you know?
Patients who received focused attention from pharmacists when transitioning from different levels of care expressed higher satisfaction, according to research presented at the American Society of Health-System Pharmacists’ Clinical Meeting.
A Saudi survey found that 41% of Saudi consumers prefer to consult with pharmacists on prescription medication and 48% consumers want pharmacists to increase counselling about their medications. Consumer counselling is reported to be practiced in 62.2% (USA), 25% (UK), and over 50% (Canada) of the cases.
71% of UAE survey respondents search medical information online according to data by BCG, further underlining pharmacies’ potential to raise awareness and offer advice
“Empowered Pharmacists can play a critical and complementary role alongside healthcare professionals in helping improve condition awareness, diagnoses, management and adherence. I look forward to connecting with leading healthcare experts and pharmacists from across Middle East and Asia to n this first of its kind multidisciplinary symposium and to make meaningful scientific exchanges and connections across therapeutic specialties.” shared Prof Ibrahim, Professor of Pharmaceutics and Pharmaceutical Biotechnology, King Saud University, moderator at the symposium.
“Aligned to World Pharmacists Day theme of ‘Pharmacy united in action for a healthier world’, the symposium will also celebrate the stellar efforts of Pharmacists in creating a positive impact on health in Middle East,” added Dr Barlow.
Symposium Speakers include:
Holistic Health Session
Prof Philip Calder
Prf Jean-Marc Dersot
Diabetes & Neurology Session
Prof Carlos Albert Calderon Ospina
Dr Andre Priede
Cardiac & Respiratory Health Session
Prof Ivan Darby
Dr Antonio Chua
Prof Ibrahim Alsarra
Dr Marina Kamel
Prof Rima Obeid
Asst Prof Dr Nadia Al Mazrouei
For Information/Registration for the 1st P&G Health Middle East Whole Body Health Symposium: https://us02web.zoom.us/webinar/register/6616626418217/WN_1ZWTfFqsSmiFnpLtahfdAw
Email id: email@example.com
About P&G Health:
P&G Health, the health care division of P&G company, drives consumer-centric innovation to empower our consumers to live longer, healthier, and more vibrant lives. The P&G Health portfolio includes leading brands in Respiratory with Vicks® and Nasivin®, Pregnancy with Femibion® and Clearblue®, Oral Care with Crest® and Oral-B®, Vitamins and Minerals Supplementation with Bion3®, Seven Seas®, Evion® and Sangobion®, Digestive wellness with Metamucil®, Prilosec OTC®, Pepto Bismol® and Align®, Nerve Care with Neurobion® and Pain Relief with Dolo-Neurobion®.
About P&G Health Middle East:
P&G strives to improve the lives of 90 million consumers in the Arabian Peninsula & Levant region. Our portfolio consists of leading iconic brands such as Neurobion, Vicks, Seven Seas, and Femibion which have been trusted by patients & health care professionals for decades.
About Procter & Gamble:
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide.
For more information, please contact:
View original content:https://www.prnewswire.com/news-releases/uniting-in-action-for-a-healthier-middle-east-301626132.html
SOURCE P&G Health
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infection. The trial did not achieve its primary endpoint, as measured by comparing the rate of sustained clinical resolution of symptoms of COVID-19 at day 14 of Tempol versus placebo. Last year, the company started dosing in the Phase 2/3 trial for Tempol, which was designed to enroll 248 patients. Th
The company has also secured commitments from a syndicate of investors — which include Penn Medicine — for a $30 million financing.
To avert a collision of patents and safety regulations, the Supreme Court must ensure that a damaging ruling is quickly undone.
The gene-sequencing company is fighting antitrust regulators on two continents as it seeks to hold on to Grail, which it bought last year.
A Food and Drug Administration advisory committee is set to meet this week to discuss three cancer therapies. The Oncologic Drugs Advisory Committee is set to meet Wednesday to vote whether the benefits of Spectrum Pharmaceuticals Inc.'s treatment of patients with certain types of non-small cell lung cancer outweigh the risks. The same day the committee is also set to discuss Pepaxto, Oncopeptides AB' investigational multiple myeloma treatment that received an accelerated approval in early 2021.
Across the U.S., the climate crisis is threatening the ability of thousands of community health centers care for millions of uninsured or underinsured patients. To address climate-related risks to …
As biotech companies take new shots at fatty liver disease, investor skepticism and potential payoffs are high.
How is the new COVID-19 booster different from the previous booster and should I get it?
Some in the White House believe that Biden’s statement was far from the controversial declaration of victory described – and lamented – in some media reports.
Undaunted by a potential battle with a goliath like Pfizer, Prometheus is developing PRA023, an experimental treatment for inflammatory bowel disease. Prometheus' candidate could eventually generate billions in annual revenue, but it will have to overcome PF-06480605, a similar candidate from Pfizer. Can Prometheus take on Pfizer in the lucrative space for inflammatory bowel disease treatments?
Immunic Inc (NASDAQ: IMUX) announced unblinded safety, tolerability, and pharmacokinetic (PK) results from Part A (single ascending doses, SAD) and Part B (multiple ascending doses, MAD) of its phase 1 trial of IMU-856 in healthy human subjects. In the SAD part of phase 1 clinical trial, healthy human subjects were randomized to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg. Single ascending doses of IMU-856 were found
In many ways, the past two and a half years of life under the COVID-19 pandemic have felt like an eternity. From all the ways we've changed our daily lives to the risks we now face whenever we venture outside our doors, it can still feel like the virus is a presence we can't seem to shake. But now, as many of the last health precautions are lifted and public life is beginning to normalize, there's evidence that new threats from COVID are emerging—including one side effect that a new study says "
Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir
By Mark Gilman, Benzinga
UCSF infectious disease Dr. Peter Chin-Hong disagrees with Biden that pandemic is over.
A mask that can detect coronavirus in just 10 minutes has been developed by scientists.
Paul WarnerWith more than 27,000 people still hospitalized with COVID-19 on any given day nationwide, and more than 500 of them dying and winter on the horizon President Joe Biden made a surprising assessment of the state of the pandemic on Sunday night.“The pandemic is over,” Biden said in an interview on CBS' 60 Minutes. “We still have a problem with COVID. We’re still doing a lot of work on it. But the pandemic is over.”A statement with that degree of public impact would normally be announced
Some Colgate products, Trojan condoms and Clearblue pregnancy tests sold at Family Dollar are being recalled after being improperly stored.
BBLs are the wave right now.
England's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable. This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales. Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia